• Trendlyne logo
  • Markets
  • Alerts
  • F&O
  • MF
  • Reports
  • Screeners
  • Subscribe
  • Superstars
  • Portfolio
  • Watchlist
  • Insider Trades
  • Results
  • Data Downloader
  • Events Calendar
  • What's New
  • Explore
  • FAQs
  • Widgets
More
    Search stocks
    IND USA
    IND
    IND
    IND
    USA
    • Stocks
    • Futures & Options
    • Mutual Funds
    • News
    • Fundamentals
    • Reports
    • Corporate Actions
    • Alerts
    • Shareholding
    logo
    Cipla Ltd.
    09 May 2025
    1517.70
    0.31%
    Cipla Q4 Results Preview: India, South Africa To Drive Growth As US Market Softens
    Cipla Q4 Results Preview: India, South Africa To Drive Growth As US Market Softens
    NDTV Profit
    In contrast to the US market, Cipla's India business is expected to exhibit strong growth, with projections of 9-10% year-on-year growth.
    Copy LinkShare onShare on Share on Share on
    Cipla Ltd. is trading above its 200 day SMA of 1496.1
    logo
    Dr. Reddy's Laboratories Ltd.
    08 May 2025
    1248.10
    0.27%
    Dr. Reddy's Q4 Results Preview: Biosimilars To Drive Revenue Growth
    Dr. Reddy's Q4 Results Preview: Biosimilars To Drive Revenue Growth
    NDTV Profit
    Dr. Reddy's revenue is estimated to rise 15% year-on-year to Rs 8,359.7 crore.
    Copy LinkShare onShare on Share on Share on
    Dr. Reddy's Laborato.. has an average target of 1278.56 from 9 brokers.
    Dr Reddy's Q4 Results: Date, Dividend News, Earnings Call Schedule And Other Key Details
    NDTV Profit | 08 May 2025 1 more
    Dr Reddy's Q4 results preview: Analysts eye 18% jump in PAT; check details
    Business Standard | 08 May 2025
    logo
    Alembic Pharmaceuticals Ltd.
    07 May 2025
    910.40
    0.67%
    Alembic Pharma Q4 Review: Dolat Capital Upgrades Rating To 'Add', Hikes Target Price Post Inline Results
    Alembic Pharma Q4 Review: Dolat Capital Upgrades Rating To 'Add', Hikes Target Price Post Inline Results
    NDTV Profit
    Given the recent correction in Alembic Pharma's stock price there is a decent upside, hence Dolat Capital upgrades rating to Accumulate' from Reduce
    Copy LinkShare onShare on Share on Share on
    Number of FII/FPI investors decreased from 198 to 192 in Jun 2025 qtr
    Alembic Pharma Q4 profit dips 12%, revenue rises 17% to Rs 1,770 cr
    Business Standard | 06 May 2025
    logo
    Aarti Drugs Ltd.
    06 May 2025
    491.60
    0.73%
    Aarti Drugs Q4 Results: Profit Jumps 33%
    Aarti Drugs Q4 Results: Profit Jumps 33%
    NDTV Profit
    The margin narrowed to 13.8% in the quarter ended March.
    Copy LinkShare onShare on Share on Share on
    Number of FII/FPI investors decreased from 96 to 73 in Jun 2025 qtr
    logo
    Glenmark Pharmaceuticals Ltd.
    06 May 2025
    1980.20
    1.07%
    Glenmark Pharma shares up 2% after FDA grants fast track status to cancer drug
    Glenmark Pharma shares up 2% after FDA grants fast track status to cancer drug
    Economic Times
    Glenmark Pharma's innovation arm, IGI, received FDA fast track designation for its myeloma therapy ISB 2001, targeting heavily pre-treated RRMM patients. The tri-specific antibody showed high response rates and a favorable safety profile in early trials. Complete results will be presented at ASCO 2025. The stock rose 2.2% on Monday, with analysts maintaining a 'Buy' rating.
    Copy LinkShare onShare on Share on Share on
    Number of FII/FPI investors decreased from 404 to 396 in Jun 2025 qtr
    logo
    Alembic Pharmaceuticals Ltd.
    02 May 2025
    910.40
    0.67%
    Alembic Pharma Gains USFDA Nod For Generic Heart Attack And Stroke Prevention Drug
    Alembic Pharma Gains USFDA Nod For Generic Heart Attack And Stroke Prevention Drug
    NDTV Profit
    The company's approved ANDA is therapeutically equivalent to AstraZeneca Pharmaceuticals's Brilinta Tablets, 60 mg and 90 mg, it added.
    Copy LinkShare onShare on Share on Share on
    Alembic Pharmaceuticals Ltd. is trading below all available SMAs
    logo
    Ajanta Pharma Ltd.
    02 May 2025
    2401.80
    0.15%
    Ajanta Pharma Q4 Review: Revenue Inline But Margins Contract- Systematix Maintains 'Buy', Cuts Target Price
    Ajanta Pharma Q4 Review: Revenue Inline But Margins Contract- Systematix Maintains 'Buy', Cuts Target Price
    NDTV Profit
    Systematix retains Buy with a revised target price of Rs 3,293 based on 35x FY27E earnings per share.
    Copy LinkShare onShare on Share on Share on
    Ajanta Pharma Ltd. has lost -27.76% in the last 1 Year
    logo
    AstraZeneca Pharma India Ltd.
    01 May 2025
    9331.00
    1.18%
    AstraZeneca, Qure.ai complete AI-enabled assessment of 5 million chest X-rays for lung cancer
    Business Line
    In 2020, AstraZeneca partnered with Qure.ai to leverage its technology for assessing chest X-rays and determining potential lung cancer risk.
    Copy LinkShare onShare on Share on Share on
    AstraZeneca Pharma India Ltd. is trading above all available SMAs
    logo
    Alkem Laboratories Ltd.
    01 May 2025
    5442.00
    -0.32%
    Alkem Lab's Sarvesh Singh buys duplex on Mumbai's Carter road for Rs 174 cr
    Business Standard
    The sea-facing duplex is spread across 12,148 square feet and occupies two entire floors.
    Copy LinkShare onShare on Share on Share on
    Alkem Laboratories L.. has an average target of 5463.50 from 2 brokers.
    logo
    Gland Pharma Ltd.
    30 Apr 2025
    1951.40
    -1.52%
    Gland Pharma gets USFDA nod for Vyzulta generic with 180-day exclusivity
    Business Standard
    Gland Pharma on Wednesday said it has received approval from the US health regulator for a generic medication to treat conditions related to high pressure in the eye. The company has received approval from the US Food and Drug Administration (USFDA) for its abbreviated new drug application for Latanoprostene Bunod Ophthalmic Solution, (0.024 per cent), the drug firm said in a statement. The company's product is bioequivalent and therapeutically equivalent to Bausch and Lomb, Inc's Vyzulta ophthalmic solution, it added. The product is indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. The company is the exclusive first-to-file and is eligible for 180 days of generic drug exclusivity, Gland Pharma said. According to IQVIA, the product had sales of around USD 171 million in the US for the 12 months ending February 2025. Shares of Gland Pharma on Wednesday ended 1.04 per cent down at Rs 1,398.35 apiece on the BSE.
    Copy LinkShare onShare on Share on Share on
    Gland Pharma Ltd. is trading above its 200 day SMA of 1711.0
    more
    loading
    Trendlyne Logo Trendlyne
    Stay ahead of the market
    Markets Today
    • Nifty 50 today
    • Sensex today
    • Latest Quarterly results
    • FII & DII data today
    Dashboard
    • Industry & Sector analysis
    • ETFs
    • Mutual Funds
    • Bullish & Bearish spread
    • Global Indices
    Tools
    • Compare stocks
    • Widgets
    • Data Downloader
    • Excel Connect
    IPOs
    • Dashboard (Mainboard & SME)
    • Upcoming IPOs
    • Recently Listed IPOs
    • Most Successful IPOs
    Upcoming IPOs
    • DSM Fresh Foods
    • Greenleaf Envirotech
    • NSB BPO Solutions
    Quick Links
    • Contact us
    • Blogs
    • FAQs
    Company
    • Privacy
    • Terms of Use
    • Disclaimer
    Trendlyne Products
    • Starfolio
    • SmartOptions
    • Trendlyne US Global
    Get Mobile App
    • Android
    • iOS

    Copyright © 2025 Giskard Datatech Pvt Ltd (RA SEBI Reg No: INH000022507)